2-ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid | 1149761-17-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid
• 英文别名: 4Z,7Z,10Z,13Z,16Z,19Z-2-ethyldocosahexaenoic acid；(all-Z)-2-ethyldocosa-4,7,10,13,16,19-hexaenoic acid；(4Z,7Z,10Z,13Z,16Z,19Z)-2-ethyldocosa-4,7,10,13,16,19-hexaenoic acid
• CAS: 1149761-17-0
• 化学式: C₂₄H₃₆O₂
• 分子量: 356.549
• InChiKey: PNLQMIOPVBCLRV-YNUSHXQLSA-N

物化性质

• 沸点：
  468.7±24.0 °C(predicted)
• 密度：
  0.934±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  26
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 114.0h， 生成 l,3-bis(trifluoroacetyl)-2-PRB-2
  参考文献：
  名称：

  새로운 ＤＨＡ 유도체 및 약물로서 그들의 사용

  摘要：

  该发明涉及一般化学式（Ⅰ）的化合物，以及其药学上可接受的盐，溶剂物，复合物和前体药物（前药）; 用于治疗各种疾病和状态。例如，用作降低高三酰甘油水平（即高胆固醇），降低非HDL胆固醇，降低葡萄糖和HbAlc以及改善胰岛素抵抗的药物：[化学式Ⅰ]其中R和R相同或不同，选择自氢原子，羟基，烷基，卤素原子，烷氧基，酰氧基，酰基，醇基，烷基基，芳基，烷硫基，烷氧羰基基，烷基苯基基，烷基磺酰基基，烷基磺酰基基，氨基，烷基氨基基。本发明还涉及包含化学式（Ⅰ）化合物的药学组合物，以及与化学式（Ⅰ）相应的化合物的制备方法。

  公开号：

  KR20200016613A
• 作为产物：
  描述：

  ethyl (all-Z)-2-ethyldocosa-4,7,10,13,16,19-hexaenoate 在 水 、 lithium hydroxide 作用下， 以 乙醇 为溶剂， 反应 18.0h， 以200 mg的产率得到2-ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid
  参考文献：
  名称：

  [EN] LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE
  [FR] COMPOSÉS LIPIDIQUES ET COMPOSITIONS ASSOCIÉES ET LEUR UTILISATION OPHTALMIQUE

  摘要：

  本发明涉及用于预防或治疗如视网膜退行性疾病和眼部炎症疾病的眼科疾病的一类脂质化合物公式(I)及其药用可接受盐：(I)（其中R1为C9至C22的烷基或具有1至6个双键的C9至C22的烯基；R2选自卤素原子、羟基、烷基、烷氧基、烷硫基、羧基、酰基、氨基和烷基氨基的组；R3为氢原子或R2基团；R4为羧酸或其衍生物；X为亚甲基(-CH2-)，或氧或硫原子）。

  公开号：

  WO2017093732A1

文献信息

• [EN] NEW DHA DERIVATIVES AND THEIR USE AS MEDICAMENTS<br/>[FR] NOUVEAUX DÉRIVÉS DE DHA ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS
  申请人：PRONOVA BIOPHARMA NORGE AS

  公开号：WO2009056983A1

  公开（公告）日：2009-05-07

  The present disclosure relates to compounds of the general Formula (I): wherein R1 and R2 are the same or different and are chosen from a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, and an alkylamino group; and any pharmaceutically acceptable salt, solvate, complex, or pro-drug thereof; and their use as medicaments for the treatment of various diseases and conditions, for example, reduction of elevated triglyceride levels, i.e., hypertriglyceridemia, reduction of non-HDL cholesterol, reduction of glucose and HbAIc, and improvement of insulin resistance. The present disclosure also relates to a pharmaceutical composition comprising compounds of formula (I), as well as to processes for preparing compounds according to formula (I).

  本公开涉及一般式（I）的化合物，其中R1和R2相同或不同，选择自氢原子、羟基、烷基、卤原子、烷氧基、酰氧基、酰基、烯基、炔基、芳基、烷硫基、烷氧羰基、烷基亚砜基、烷基磺酰基、氨基和烷基氨基；以及其任何药学上可接受的盐、溶剂化合物、复合物或前药；以及它们作为治疗各种疾病和病况的药物的用途，例如降低高三酸甘油酯水平，即高三酸甘油酯血症，降低非HDL胆固醇，降低葡萄糖和HbAIc，改善胰岛素抵抗力。本公开还涉及包含式（I）化合物的药物组合物，以及根据式（I）制备化合物的方法。
• OMEGA-3 LIPID COMPOUNDS
  申请人：Pronova Biopharma Norge AS

  公开号：EP2102139A2

  公开（公告）日：2009-09-23
• JP2010508262A
  申请人：——

  公开号：JP2010508262A

  公开（公告）日：2010-03-18
• Novel Compounds
  申请人：Bryhn Morten

  公开号：US20080300306A1

  公开（公告）日：2008-12-04

  Compounds of formula (I); wherein R 1 and R 2 are the same or different and may be selected from the group consisting of a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, and an alkylamino group; and X represents a carboxylic acid group, a carboxylate group, or a carboxamide group; or any pharmaceutically acceptable salt, solvate, complex or pro-drug thereof, with the provisos that the compound of formula (I) is not (all-Z)-4,7,10,13,16,19-docosahexaenoic acid (DHA), alpha-methyl-DHA, alpha-methyl DHA methyl ester, alpha-methyl-DHA ethyl ester or alpha-hydroxy DHA ethyl ester, are disclosed. A fatty acid composition and a pharmaceutical composition comprising such compounds are also disclosed. The use of such compounds as medicaments, in particular for the treatment of diabetes type 2, is also disclosed.
• DHA DERIVATIVES AND THEIR USE AS MEDICAMENTS
  申请人：Holmeide Anne Kristin

  公开号：US20100267828A1

  公开（公告）日：2010-10-21

  The present disclosure relates to compounds of the general formula (I): wherein R 1 and R 2 are the same or different and are chosen from a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, and an alkylamino group; or any pharmaceutically acceptable salt, solvate, complex, or pro-drug thereof; and their use as medicaments for the treatment of various diseases and conditions, for example, reduction of elevated triglyceride levels, i.e., hypertriglyceridemia, reduction of non-HDL cholesterol, reduction of glucose and HbA1c, and improvement of insulin resistance. The present disclosure also relates to a pharmaceutical composition comprising compounds of formula (I), as well as to processes for preparing compounds according to formula (I).